In the COP-AF study, investigators sought to determine whether colchicine could effectively reduce the incidence of perioperative atrial fibrillation (AF) and myocardial injury after non-cardiac surgery (MINS) in individuals undergoing thoracic surgery. The study had a dual primary endpoint, focusing on clinically significant perioperative AF or atrial flutter, as well as MINS occurring within 14 days following randomization.
The results of the study revealed that AF developed in 6.4% of patients who were assigned to receive colchicine, while 7.5% of patients who were assigned to the placebo group experienced AF during the perioperative period. Similarly, MINS was observed in 18.3% of patients treated with colchicine and in 20.3% of patients who received the placebo. It is noteworthy that these findings did not reach clinical significance.
Learn more about the interesting studies presented at ESC Congress 2023.
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.
